Business Wire
22 Jun 2026, 10:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Merck's Phase 3 ATLAS-UC induction-only study for tulisokibart (MK-7240) successfully met its primary endpoint of clinical remission in patients with moderately to severely active UC. — Positive Phase 3 results for a drug targeting a major indication like Ulcerative Colitis significantly increase the probability of FDA approval and future revenue streams.
+0.60Which stocks this story touches
The company announced positive topline results from a Phase 3 study for its investigational antibody tulisokibart.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
15h ago
